 anthracycline antibiotic doxorubicin produces characteristic myopathy cardiac muscle limits use cancer therapy. shown cultured neonatal rat cardiac muscle cells doxorubicin treatment resulted rapid, selective decrease expression muscle-specific genes, preceded changes characteristic doxorubicin cardiomyopathy. Doxorubicin selectively dramatically decreased levels mRNA sarcomeric genes, alpha-actin, troponin I, myosin light chain 2, well muscle-specific, nonsarcomeric isoform creatine kinase. However, doxorubicin affect nonmuscle gene transcripts (pyruvate kinase, ferritin heavy chain, beta-actin). Actinomycin D, inhibitor DNA-dependent RNA polymerase, show similar selective decrease muscle-specific mRNAs but, rather, produced nonspecific, dose-dependent decrease muscle nonmuscle transcripts. doxorubicin effect muscle gene expression limited cardiac muscle; cultured skeletal myocytes resistant effects doxorubicin 100-fold greater doses causing changes mRNA levels cardiac muscle cells. effects doxorubicin reproduced vivo; rats injected doxorubicin showed dose-dependent decrease levels mRNAs alpha-actin, troponin I, myosin light chain 2, isoform creatine kinase cardiac skeletal muscle. selective changes gene expression cardiocyte cultures cardiac muscle precede classical ultrastructural changes may explain myofibrillar loss characterizes doxorubicin cardiac injury.